Melinta Therapeutics’ New Drug Application for Baxdela Accepted for Filing by US FDA

Melinta Invited to Present at Annual JP Morgan Healthcare Conference

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) for IV and oral Baxdela™ (delafloxacin) for filing and granted Priority Review status to both NDAs. The acceptance of the NDAs indicates that the FDA has deemed the applications sufficiently complete to allow a substantive review.